Bharat Immunolog

{
  "main_header": {
    "sid": 936506,
    "name": "Bharat Immunolog",
    "stock_name": "Bharat Immunolog",
    "full_name": "Bharat Immunological & Biological Corporation Ltd",
    "name_url": "stocks-analysis/bharat-immunolog",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "19.38",
    "chg": -0.77,
    "chgp": "-3.82%",
    "dir": -1,
    "prev_price": "20.15",
    "mcapval": "86.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524663,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE994B01014",
    "curr_date": "Feb 09",
    "curr_time": "",
    "bse_nse_vol": "46.9 k",
    "exc_status": "Active",
    "traded_date": "Feb 09, 2026",
    "traded_date_str": "2026 02 09",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bharat-immunolog-936506-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Bharat Immunological & Biological Corporation Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bharat-immunological-biological-corporation-ltd-fallingrising-3821413",
        "imagepath": "",
        "date": "2026-02-05 00:56:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Robust Weekly Performance Drives Momentum</strong></p>\n<p>The stock has delivered an impressive 17.93% return over the last seven days, significantly outpacing the Sensex’s modest 1.79% gain during the same period. This strong weekly performance has been a key driver behind the recent price appreciation. Investors appear to be responding favourably to the stock’s resilience and relative strength, especially given the broader market’s subdued performance.</p>\n<p>Moreover, the stock has been on a consistent upward trajectory, registering gains for seven consecutive days and accumulating a 20.06% return in that span. Such sustained momentum often attracts increased investor attention, contributing to further price appreciation.</p>\n<div class=\"promo-strategy-box\">\n<p><strong>Transformation in f..."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-immunological-biological-corporation-ltd-is-rated-strong-sell-3811083",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatImmunolog_mojoScore_3811083.png",
        "date": "2026-01-30 10:11:02",
        "description": "Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 30 January 2026, providing investors with the most recent and relevant data to understand the stock’s standing today."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd Falls to 52-Week Low of Rs.16.76",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bharat-immunological-biological-corporation-ltd-falls-to-52-week-low-of-rs1676-3796872",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatImmunolog_priceRelatedfactors_3796872.png",
        "date": "2026-01-20 15:57:12",
        "description": "Shares of Bharat Immunological & Biological Corporation Ltd have declined to a fresh 52-week low of Rs.16.76, marking a significant downturn amid broader market pressures and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and recent performance metrics."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd Hits 52-Week Low at Rs.16.76",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bharat-immunological-biological-corporation-ltd-hits-52-week-low-at-rs1676-3796870",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatImmunolog_priceRelatedfactors_3796870.png",
        "date": "2026-01-20 15:57:01",
        "description": "Bharat Immunological & Biological Corporation Ltd’s stock declined to a fresh 52-week low of Rs.16.76 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock has underperformed its Pharmaceuticals & Biotechnology peers and the benchmark Sensex over the past year, reflecting ongoing financial and performance concerns."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-immunological-biological-corporation-ltd-is-rated-strong-sell-3794021",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatImmunolog_mojoScore_3794021.png",
        "date": "2026-01-19 10:10:32",
        "description": "Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 19 January 2026, providing investors with an up-to-date view of its performance and outlook."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-immunological-biological-corporation-ltd-is-rated-strong-sell-3783080",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BharatImmunolog_mojoScore_3783080.png",
        "date": "2026-01-06 10:10:26",
        "description": "Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-immunological-biological-corporation-ltd-is-rated-strong-sell-3769709",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BharatImmunolog_mojoScore_3769709.png",
        "date": "2025-12-25 15:12:53",
        "description": "Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with an up-to-date view of its performance and prospects."
      },
      {
        "title": "Bharat Immunological & Biological Corporation Stock Hits 52-Week Low at Rs.18.58",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bharat-immunological-biological-corporation-stock-hits-52-week-low-amidst-continued-downtrend-3751570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BharatImmunolog_priceRelatedfactors_3751570.png",
        "date": "2025-12-08 13:17:33",
        "description": "Shares of Bharat Immunological & Biological Corporation touched a fresh 52-week low of Rs.18.58 today, marking a significant decline amid a broader market environment where the Sensex showed modest weakness. The stock has recorded a three-day consecutive decline, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bharat Immunolog Sees Revision in Market Assessment Amidst Weak Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bharat-immunolog-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-trends-3749851",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BharatImmunolog_mojoScore_3749851.png",
        "date": "2025-12-06 10:10:23",
        "description": "Bharat Immunolog, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational performance. The recent assessment highlights concerns across multiple analytical parameters, signalling caution for investors amid persistent underperformance and deteriorating fundamentals."
      }
    ],
    "total": 84,
    "sid": "936506",
    "stock_news_url": "https://www.marketsmojo.com/news/bharat-immunological-biological-corporation-936506"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBIS LODR.",
      "datetime": "07-Aug-2024",
      "details": "BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/08/2024 inter alia to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015 it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Friday 16th August 2024 for General Purpose.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBIS LODR.",
      "datetime": "29-Feb-2024",
      "details": "BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/03/2024 inter alia to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Friday 08th March 2024 for General Purpose.",
      "source": "BSE"
    },
    {
      "caption": "Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023.",
      "datetime": "13-Dec-2023",
      "details": "Submission of Draft Annual Report 2022-23 for AGM on 29.12.2023",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

2026-02-05 00:56:50

Robust Weekly Performance Drives Momentum

The stock has delivered an impressive 17.93% return over the last seven days, significantly outpacing the Sensex’s modest 1.79% gain during the same period. This strong weekly performance has been a key driver behind the recent price appreciation. Investors appear to be responding favourably to the stock’s resilience and relative strength, especially given the broader market’s subdued performance.

Moreover, the stock has been on a consistent upward trajectory, registering gains for seven consecutive days and accumulating a 20.06% return in that span. Such sustained momentum often attracts increased investor attention, contributing to further price appreciation.

Transformation in f...

Read full news article

Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell

2026-01-30 10:11:02

Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 30 January 2026, providing investors with the most recent and relevant data to understand the stock’s standing today.

Read full news article

Bharat Immunological & Biological Corporation Ltd Falls to 52-Week Low of Rs.16.76

2026-01-20 15:57:12

Shares of Bharat Immunological & Biological Corporation Ltd have declined to a fresh 52-week low of Rs.16.76, marking a significant downturn amid broader market pressures and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and recent performance metrics.

Read full news article

Bharat Immunological & Biological Corporation Ltd Hits 52-Week Low at Rs.16.76

2026-01-20 15:57:01

Bharat Immunological & Biological Corporation Ltd’s stock declined to a fresh 52-week low of Rs.16.76 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock has underperformed its Pharmaceuticals & Biotechnology peers and the benchmark Sensex over the past year, reflecting ongoing financial and performance concerns.

Read full news article

Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell

2026-01-19 10:10:32

Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 19 January 2026, providing investors with an up-to-date view of its performance and outlook.

Read full news article

Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell

2026-01-06 10:10:26

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Bharat Immunological & Biological Corporation Ltd is Rated Strong Sell

2025-12-25 15:12:53

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with an up-to-date view of its performance and prospects.

Read full news article

Bharat Immunological & Biological Corporation Stock Hits 52-Week Low at Rs.18.58

2025-12-08 13:17:33

Shares of Bharat Immunological & Biological Corporation touched a fresh 52-week low of Rs.18.58 today, marking a significant decline amid a broader market environment where the Sensex showed modest weakness. The stock has recorded a three-day consecutive decline, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Read full news article

Bharat Immunolog Sees Revision in Market Assessment Amidst Weak Financials

2025-12-06 10:10:23

Bharat Immunolog, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational performance. The recent assessment highlights concerns across multiple analytical parameters, signalling caution for investors amid persistent underperformance and deteriorating fundamentals.

Read full news article

View All News